A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

Indigenous communities in Latin America say they are missing out on life-saving HIV drugs due to a lack of representation.